Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
Last trade$5.09
Day change-$0.295 (-5.48%)
Day range$4.94 – $6.06
Volume297,842
Market cap$292M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$292.06M
Price / earnings
—
Price / book
0.76×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.6×
Profitability
Earnings per share
-$6.06
Return on assets
-46.53%
Return on equity
-85.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.21×
Quick ratio
7.21×
Cash ratio
1.49×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$287.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for EIKN, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$0
$0
$0
Cost of revenue
$0
$0
$0
Gross profit
$0
$0
$0
Selling, general and administrative
$18.73M
$17.93M
$17.29M
Research and development
$71.83M
$75.46M
$70.05M
Total operating expenses
$90.55M
$93.39M
$87.34M
Operating income
-$90.55M
-$93.39M
-$87.34M
Interest expense
$0
$0
$0
Income before taxes
-$86.11M
-$88.41M
-$82.96M
Income taxes
$0
$0
$0
Net income
-$86.11M
-$88.41M
-$82.96M
Net income attributable to common shareholders
-$86.11M
-$88.41M
-$82.96M
EBITDA
-$85.52M
-$88.27M
-$82.12M
Basic earnings per share
-$1.59
-$1.63
-$2.46
Diluted earnings per share
-$1.59
-$1.63
-$2.46
Recent news
Company coverage with links to the original publishers.
Eikon Therapeutics presented updated data for EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for first-line stage 4 NSCLC at ESMO Congress. The squamous cohort showed 72% ORR and 100% DCR with 12.9-month median duration of response. The combination was well-tolerated with an adverse event profile similar to standard-of-care alone, supporting outpatient administration. The Phase 2/3 TeLuRide-008 trial is actively enrolling with interim analysis expected in 2H 2027.
Eikon Therapeutics announced that seven abstracts from its clinical pipeline will be presented at the 2026 European Society for Medical Oncology Congress in Madrid. The presentations will cover updates on four clinical candidates including EIK1001 (TLR7/8 dual-agonist), EIK1003 and EIK1004 (PARP1 inhibitors), and EIK1005 (WRN helicase inhibitor) across various oncology indications including NSCLC, prostate cancer, and advanced solid tumors.
Eikon Therapeutics presented updated clinical data for its lead oncology programs at ASCO 2026. EIK1001, a TLR7/8 dual agonist, demonstrated a 63.1% objective response rate and 90.8% disease control rate in first-line NSCLC when combined with pembrolizumab and chemotherapy, with a favorable safety profile supporting outpatient administration. EIK1003, a PARP1-selective inhibitor, showed monotherapy activity and promising initial combination data with paclitaxel in heavily pretreated patients.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.